Form 4: ENZO BIOCHEM CEO Disposes Shares Post-Merger

ENZO BIOCHEM's CEO, Kara Cannon, reported the disposition of common stock and cancellation of stock options following the company's merger with Bethpage Parent, Inc. for $0.70 per share.

Summary

• Kara Cannon, Chief Executive Officer, Director, and 10% Owner of ENZO BIOCHEM INC, reported changes in her beneficial ownership on August 20, 2025.
• The changes resulted from the merger of ENZO BIOCHEM INC with Bethpage Merger Sub, Inc., a wholly-owned subsidiary of Bethpage Parent, Inc., as per the Agreement and Plan of Merger dated June 23, 2025.
• At the effective time of the merger, each share of ENZO BIOCHEM's common stock was canceled and automatically converted into the right to receive $0.70 in cash, without interest and less any applicable withholding taxes.
• Cannon disposed of 359,737 shares of common stock held directly, which included 100,000 Restricted Stock Units (RSUs) that also converted to cash at the merger consideration.
• An additional 45,065 shares of common stock held indirectly through a 401k were also disposed of.
• All outstanding stock options held by Cannon, totaling 630,400, were automatically canceled at the effective time of the merger without any cash payment or other consideration.

Sentiment

Score: 6

Explanation: The filing is a factual report of a completed merger transaction. For shareholders, the cash consideration is a positive liquidity event, but for option holders whose options were canceled without value, it represents a loss. Overall, it's a neutral report of a corporate action.

Positives

• The merger provided a definitive cash payout of $0.70 per share for common stockholders, including the CEO's directly and indirectly held shares and RSUs, ensuring liquidity for these holdings.

Negatives

• Stock options held by the CEO, totaling 630,400, were canceled without any cash payment or consideration, indicating they were likely out-of-the-money relative to the $0.70 merger price.

Future Outlook

NA

Industry Context

This filing reflects the completion of an acquisition, a common occurrence in the biotechnology and diagnostics industry, often driven by strategic consolidation or the realization of value for shareholders. The specific terms of the merger, such as the $0.70 per share consideration, would typically be evaluated against the company's historical performance and market valuations of comparable firms to assess the deal's attractiveness.

Comparison to Industry Standards

• The $0.70 per share merger consideration for ENZO BIOCHEM INC (ENZB) would typically be assessed against the company's pre-merger stock price, its intrinsic value, and valuation multiples from comparable acquisitions in the diagnostics or life sciences sector.
• For example, similar transactions in the diagnostics space, such as recent acquisitions by larger players like Quest Diagnostics or LabCorp, often involve premiums over the target's unaffected share price. Without the pre-merger stock price, the premium or discount cannot be determined.
• The cancellation of out-of-the-money stock options is a standard practice in mergers where the acquisition price falls below the option's strike price, a common outcome in many corporate takeovers, particularly in sectors with volatile stock performance or long-dated options.

Stakeholder Impact

• Shareholders: Received $0.70 cash per share, marking the conclusion of their investment in ENZO BIOCHEM as a publicly traded entity.
• Employees (specifically option holders): Those holding stock options, including the CEO, saw their options canceled without value if the strike price exceeded the merger consideration.

Key Dates

Recommendation

The company has been acquired, and its common stock has been converted into the right to receive $0.70 in cash per share. For any remaining shares, the recommendation is to sell to realize the cash value, as the company is now a wholly-owned subsidiary and no longer publicly traded.

Keywords

ENZO BIOCHEM, ENZB, SEC Form 4, Merger, Beneficial Ownership, Stock Disposition, Stock Options, Restricted Stock Units, Kara Cannon, Corporate Action, Cash Merger